作者
E Wesley Ely, Athimalaipet V Ramanan, Cynthia E Kartman, Stephanie de Bono, Ran Liao, Maria Lucia B Piruzeli, Jason D Goldman, José Francisco Kerr Saraiva, Sujatro Chakladar, Vincent C Marconi, Jorge Alatorre-Alexander, Javier David Altclas, Marcelo Casas, Valeria CevoliRecio, Todd Ellerin, Kleber Giovanni Luz, Jason D Goldman, Maria Patelli Juliani Souza Lima, Akram Khan, Priscila Paulin, Ana Carolina Procopio Carvalho, Gustavo Rojas Velasco, Jose Francisco Kerr Saraiva, Imad Shawa, Jesus Simon Campos, Brian Tiffany, Adilson Westheimer Cavalcante
发表日期
2022/4/1
期刊
The Lancet Respiratory Medicine
卷号
10
期号
4
页码范围
327-336
出版商
Elsevier
简介
Background
The oral, selective Janus kinase 1/2 inhibitor baricitinib has shown efficacy in studies of hospitalised adults with COVID-19. COV-BARRIER (NCT04421027) was a multinational, phase 3, randomised, double-blind, placebo-controlled trial of baricitinib in patients with confirmed SARS-CoV-2 infection. We aimed to evaluate the efficacy and safety of baricitinib plus standard of care in critically ill hospitalised adults with COVID-19 requiring invasive mechanical ventilation or extracorporeal membrane oxygenation.
Methods
This exploratory trial followed the study design of COV-BARRIER in a critically ill cohort not included in the main phase 3 trial. The study was conducted across 18 hospitals in Argentina, Brazil, Mexico, and the USA. Participants (aged ≥18 years) hospitalised with laboratory-confirmed SARS-CoV-2 infection on baseline invasive mechanical ventilation or extracorporeal membrane …
学术搜索中的文章
EW Ely, AV Ramanan, CE Kartman, S de Bono, R Liao… - The Lancet Respiratory Medicine, 2022
EW Ely, AV Ramanan, CE Kartman, S de Bono, R Liao… - Open Forum Infectious Diseases, 2021